Scaling Global Vaccine Mega-Trials For A Top Five Pharma

Vaccine programs demand a different operational playbook than traditional clinical trials. With enrollment volumes reaching tens of thousands, compressed timelines, and the need for near real-time safety oversight, even small inefficiencies can quickly become risks. This case study explores how a top-5 global biopharma organization scaled global influenza vaccine mega-trials across the U.S. and Belgium by establishing a repeatable, centralized clinical trial ecosystem.

The program focused on speed, reliability, and data integrity — supporting rapid builds, one- to three-day data change turnaround, and automated daily safety data delivery. Advanced, dynamic symptom diaries enabled responsive follow-up based on participant inputs, while real-time dashboards strengthened sponsor oversight. A foundational pilot study stress-tested high-volume workflows, validated daily data transfers, and informed platform enhancements before full-scale deployment.

The results demonstrate what’s possible when technology and operations are purpose-built for vaccine trials: rapid cohort enrollment, strong first-week diary compliance, and consistent delivery against aggressive timelines. The approach created a scalable blueprint now supporting future global vaccine studies.

Explore the full case study to see how large-scale vaccine trials can be executed with confidence.